Lunai Bioworks Inc (LNAI)

Jun 17, 2026, 9:15 AM EDT - 6 weeks ago

LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

2026-05-28T14:26:23.000Z - 2 months ago

Lunai Bioworks and BrainStorm launch foundation for neurological diseases

May 28, 2026, 9:15 AM EDT - 2 months ago

Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration

May 22, 2026, 9:15 AM EDT - 2 months ago

Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock

2026-05-21T23:50:36.000Z - 2 months ago

Lunai Bioworks Inc. trading halted, news pending

2026-05-20T13:21:05.000Z - 2 months ago

Lunai Bioworks announces reverse stock split

May 20, 2026, 9:15 AM EDT - 2 months ago

LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT

May 15, 2026, 7:00 AM EDT - 2 months ago

Lunai Bioworks Quarterly report: Q3 2026

May 12, 2026, 12:12 AM EDT - 3 months ago

Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock

May 8, 2026, 9:00 AM EDT - 3 months ago

Lunai Bioworks Transcript: AGM 2026

May 4, 2026, 9:35 AM EDT - 3 months ago

Lunai Bioworks Completes $20 Million Preferred Issuance to Acquire CNS Delivery and Neurotherapeutic IP

May 1, 2026, 8:00 AM EDT - 3 months ago

Lunai Bioworks Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Lunai Bioworks Proxy statement: Proxy filing

Apr 15, 2026, 9:10 AM EDT - 3 months ago

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

Apr 15, 2026, 8:00 AM EDT - 3 months ago

Lunai Bioworks Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 4 months ago

Lunai Bioworks Proxy statement: Proxy filing

Apr 7, 2026, 9:05 AM EDT - 4 months ago

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

Apr 2, 2026, 8:00 AM EDT - 4 months ago

Lunai Bioworks Proxy statement: Proxy filing

2026-03-26T12:55:26.000Z - 4 months ago

Lunai Bioworks acquires BBB delivery platform in Alzheimer’s for $20M

Mar 26, 2026, 8:50 AM EDT - 4 months ago

Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer's Therapies with Broad CNS Delivery Applications

2026-03-19T14:10:31.000Z - 4 months ago

Lunai Bioworks announces formation of Pathfinder Consortium

Mar 19, 2026, 9:57 AM EDT - 4 months ago

Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

2026-03-17T12:29:40.000Z - 4 months ago

Why Is Lunai Bioworks Stock (LNAI) Rallying Today?

2026-02-19T13:47:50.000Z - 5 months ago

Lunai Bioworks granted U.S. patent for AI drug discovery system

Feb 19, 2026, 8:30 AM EST - 5 months ago

Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

Feb 17, 2026, 7:00 AM EST - 5 months ago

Lunai Bioworks Quarterly report: Q2 2026

Feb 13, 2026, 8:31 AM EST - 6 months ago

Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

2026-02-09T16:25:07.000Z - 6 months ago

Lunai Bioworks CEO says established three ‘scalable revenue generating engines’

2026-02-09T14:20:50.000Z - 6 months ago

Lunai Bioworks announces oncology collaboration with a clinical-stage partner

Feb 9, 2026, 9:15 AM EST - 6 months ago

Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data

Feb 5, 2026, 7:00 AM EST - 6 months ago

Lunai Bioworks Slides: Investor presentation

Jan 27, 2026, 10:36 AM EST - 6 months ago

Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons

2026-01-26T14:35:53.000Z - 6 months ago

Lunai Bioworks expands AI program into commercial AUD drug discovery

Jan 26, 2026, 9:30 AM EST - 6 months ago

Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

Dec 18, 2025, 9:00 AM EST - 8 months ago

Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance

Dec 9, 2025, 7:45 AM EST - 8 months ago

Lunai Bioworks Identifies Three Parkinson's Subtypes and Prioritized Drug Targets to Accelerate Proof-of-Concept Programs and Strategic Partnerships in a $13B Market

2025-11-25T12:55:12.000Z - 8 months ago

Lunai Bioworks’ immune cell therapy shows tumor regression, wins first license

Nov 25, 2025, 7:45 AM EST - 8 months ago

Lunai Bioworks Secures First Licensing LOI Following Landmark Breakthrough Showing Complete Tumor Regression in Humanized Cancer Models

Nov 14, 2025, 7:00 AM EST - 9 months ago

Lunai Bioworks Quarterly report: Q1 2026

2025-11-05T14:34:03.000Z - 9 months ago

Lunai Bioworks announces regression of tumors with immune cell therapy

Nov 5, 2025, 9:22 AM EST - 9 months ago

Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy

2025-10-30T13:41:27.000Z - 9 months ago

Lunai Bioworks announces early results from AI-based platform

Oct 30, 2025, 9:32 AM EDT - 9 months ago

Lunai Bioworks Harnesses AI and Zebrafish Data to Advance Early Detection of Neurotoxic Compounds

Oct 16, 2025, 9:45 AM EDT - 10 months ago

Landmark Study Identifies Prognostic Biomarkers in Duchenne Muscular Dystrophy Using Large-Scale Serum Proteomics

2025-10-16T13:30:37.000Z - 10 months ago

Lunai Bioworks regains compliance with Nasdaq minimum bid price rule

Oct 16, 2025, 9:15 AM EDT - 10 months ago

Lunai Bioworks Regains Compliance with Nasdaq Minimum Bid Price Requirement

Oct 15, 2025, 8:00 AM EDT - 10 months ago

Lunai Bioworks Proxy statement: Proxy Filing

Oct 6, 2025, 9:15 AM EDT - 10 months ago

Lunai Bioworks Launches AI-Powered Alzheimer's Disease Program, Expanding Neurodegenerative Pipeline

Sep 30, 2025, 9:15 AM EDT - 10 months ago

Lunai Bioworks Unveils New Corporate Identity, Streamlined Capital Structure, and Strategic Focus on AI-Powered Therapeutics and Biodefense

Sep 29, 2025, 4:00 PM EDT - 11 months ago

Lunai Bioworks Annual report: Q4 2025

Sep 25, 2025, 8:30 AM EDT - 11 months ago

Lunai Bioworks Advances Biomarker Discovery Preclinical Program in Parkinson's Disease, Positioning for Strategic Pharma Partnerships

Sep 24, 2025, 4:50 PM EDT - 11 months ago

Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split

Sep 11, 2025, 7:00 AM EDT - 11 months ago

Lunai Bioworks subsidiary BioSymetrics and Brigham and Women's Hospital Awarded NIH STTR Grant to Develop AI-Powered Platform for Alcohol Use Disorder Therapeutics

Sep 9, 2025, 8:47 AM EDT - 11 months ago

Lunai Bioworks Inc. Unveils Transformer Platform to Secure Generative AI and Accelerate Drug Discovery

Sep 8, 2025, 8:50 AM EDT - 11 months ago

Lunai Bioworks Strengthens European Strategy Through Restructuring

Sep 4, 2025, 10:05 AM EDT - 11 months ago

Lunai Bioworks Inc. Retains American Defense International

Aug 27, 2025, 9:45 AM EDT - 1 year ago

Renovaro Inc. Announces Corporate Name Change to Lunai Bioworks, Inc., Reflecting Strategic Focus on AI-Driven Biodefense, Drug Discovery and Advanced Diagnostics

Aug 8, 2025, 10:45 AM EDT - 1 year ago

Renovaro Inc. (NASDAQ: RENB) Mentioned in RealClearDefense Article on AI and Biodefense Risks

Jul 30, 2025, 8:00 AM EDT - 1 year ago

Lunai Bioworks Proxy statement: Proxy Filing

Jul 28, 2025, 10:38 AM EDT - 1 year ago

Renovaro Secures Key AI Patents, Strengthening Market Position in $20B Biomedical AI Sector

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Lunai Bioworks Proxy statement: Proxy Filing

Jul 17, 2025, 9:15 AM EDT - 1 year ago

Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy

Jul 9, 2025, 8:00 AM EDT - 1 year ago

Renovaro Strengthens Balance Sheet Through Debt Conversion and Advances AI-Driven Initiatives

Jun 30, 2025, 9:21 AM EDT - 1 year ago

Renovaro Launches AI-Based Neurotoxin Countermeasure Initiative Addressing Emerging National Security Needs

Jun 3, 2025, 9:15 AM EDT - 1 year ago

Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform

May 22, 2025, 3:12 PM EDT - 1 year ago

UPDATE - Renovaro Inc. Announces Expedited Trial for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 22, 2025, 11:05 AM EDT - 1 year ago

Renovaro Inc. Announces Expedited Trail for 2025 Lawsuit to Enforce Binding Merger Agreement with Predictive Oncology

May 15, 2025, 4:00 PM EDT - 1 year ago

Lunai Bioworks Quarterly report: Q3 2025

May 14, 2025, 9:15 AM EDT - 1 year ago

Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform

May 13, 2025, 9:15 AM EDT - 1 year ago

Renovaro and Amsterdam University Medical Center Announce Exclusive Collaboration to Advance Blood Platelet RNA Diagnostics

Apr 22, 2025, 9:20 AM EDT - 1 year ago

Renovaro Secures High-Powered Computing from Nebul Through a Partnership to Accelerate Next-Generation Biomarker Discovery and Diagnostic Programs

Apr 9, 2025, 9:25 AM EDT - 1 year ago

Renovaro and BioSymetrics Close Merger to Accelerate AI-Driven Biomarker Discovery and Precision Medicine

Apr 4, 2025, 9:40 AM EDT - 1 year ago

Renovaro Provides Update to Definitive Agreement with Predictive Oncology

Mar 3, 2025, 9:15 AM EST - 1 year ago

Renovaro Completes First Milestone Payment to Finalize Definitive Agreement with Predictive Oncology

Feb 26, 2025, 1:25 PM EST - 1 year ago

Renovaro and BioSymetrics Announce Definitive Merger Agreement to Advance AI-Driven Biomarker Discovery and Precision Medicine

Feb 26, 2025, 9:15 AM EST - 1 year ago

Renovaro Announces $15 million in Equity Committed

Feb 19, 2025, 4:00 PM EST - 1 year ago

Lunai Bioworks Quarterly report: Q2 2025

Feb 19, 2025, 11:00 AM EST - 1 year ago

Lunai Bioworks Slides: Investor Presentation

Jan 7, 2025, 6:51 PM EST - 1 year ago

PREDICTIVE ONCOLOGY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAI

AGPU

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Appoints Nathen Fuentes as Chief Financial Officer

Jan 7, 2025, 9:15 AM EST - 1 year ago

Renovaro Issues Shareholder Letter and Provides Corporate Update